Bio-Path Stock (NASDAQ:BPTH)


Chart

Previous Close

$0.06

52W Range

$0.06 - $3.39

50D Avg

$0.13

200D Avg

$0.35

Market Cap

$478.53K

Avg Vol (3M)

$61.24K

Beta

-0.03

Div Yield

-

BPTH Company Profile


Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Mar 04, 2008

Website

BPTH Performance


Latest Earnings Call Transcripts


Q2 22Aug 16, 22 | 11:34 AM
Q1 22May 17, 22 | 10:43 AM
Q4 21Mar 11, 22 | 11:01 AM

Peer Comparison


TickerCompany
RKDAArcadia Biosciences, Inc.
AKTXAkari Therapeutics, Plc
CRVOCervoMed Inc.
CAPRCapricor Therapeutics, Inc.
PULMPulmatrix, Inc.
ACHVAchieve Life Sciences, Inc.
TENXTenax Therapeutics, Inc.
SLNOSoleno Therapeutics, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks